Domov › Rakovina žlčových ciest › Kalifornia
Klinické štúdie Rakovina žlčových ciest v štáte Kalifornia
20 štúdií pre Rakovina žlčových ciest hľadá účastníkov v zariadeniach v štáte Kalifornia.
Mestá v štáte Kalifornia
Oficiálny text štúdie (anglicky)
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- City of Hope - Duarte Cancer Center, Duarte
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT06760819AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
- Research Site, Orange
- Research Site, Palo Alto
- Research Site, Santa Rosa
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT06219941A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
- City of Hope (Site 107), Duarte
- University of California at Irvine (Site 101), Orange
- UCLA Medical Center (Site 117), Santa Monica
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 29. 9. 2026 · NCT07265674Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte
- USC Norris Comprehensive Cancer Center, Los Angeles
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT05482893A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
- Research Site, Duarte
- Research Site, Los Angeles
- Research Site, Orange
- a 1 ďalších
Prebieha náborFáza 3
Vek 18 a viac · Všetky pohlavia · Aktualizované 28. 9. 2026 · NCT07221253A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
- UCLA ( Site 0317), Los Angeles
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT06428409Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Los Angeles
- Research Site, Santa Rosa
Prebieha náborFáza 2
Vek 18 až 130 · Všetky pohlavia · Aktualizované 23. 9. 2026 · NCT05489211Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- City of Hope, Duarte
- START - Los Angeles, Los Angeles
- Cedars Sinai, Los Angeles
- a 1 ďalších
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 10. 9. 2026 · NCT06293898AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, Los Angeles
- Avenzo Therapeutics Recruiting Site, Los Angeles
Prebieha náborFáza 1/2
Vek 18 až 75 · Všetky pohlavia · Aktualizované 4. 9. 2026 · NCT07038343A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Hoag Family Cancer Institute, Newport Beach
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 21. 8. 2026 · NCT06774963Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
- Research Site, Fullerton
- Research Site, La Jolla
- Research Site, Los Angeles
- a 3 ďalších
Prebieha náborFáza 3
Vek 18 až 99 · Všetky pohlavia · Aktualizované 19. 8. 2026 · NCT06467357A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Los Angeles Cancer Network, Los Angeles
- Pih Health Hematology Medical Oncology, Whittier
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 5. 8. 2026 · NCT06330064A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Precision NextGen Oncology & Research Center, Beverly Hills
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
- University of California Los Angeles Rheumatology, Westwood, Los Angeles
Prebieha náborFáza 2
Vek 8 a viac · Všetky pohlavia · Aktualizované 27. 7. 2026 · NCT05503797Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)
- University of California, Davis Comprehensive Cancer Center, Sacramento
Prebieha nábor
Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 7. 2026 · NCT06101277A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
- Cedars-Sinai Medical Center, Los Angeles
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 29. 6. 2026 · NCT07458347A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
- The City of Hope National Medical Center, Duarte
- Hoag Memorial Hospital, Newport Beach
Prebieha náborFáza 1
Vek 16 a viac · Všetky pohlavia · Aktualizované 2. 6. 2026 · NCT07197554Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
- Beverly Hills Cancer Center, Beverly Hills
- UC San Diego Moores Cancer Center, La Jolla
Prebieha náborFáza 2
Vek 18 a viac · Všetky pohlavia · Aktualizované 2. 4. 2026 · NCT05733598Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
- Stern Center for Cancer Clinical Trials and Research, Orange
Prebieha náborFáza 1
Vek 18 a viac · Všetky pohlavia · Aktualizované 5. 3. 2026 · NCT04900818Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
- Cedars-Sinai Medical Center, Los Angeles
Prebieha nábor
Vek 18 až 99 · Všetky pohlavia · Aktualizované 20. 2. 2026 · NCT04907643A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- University of Southern California, Los Angeles
Prebieha náborFáza 1/2
Vek 18 a viac · Všetky pohlavia · Aktualizované 11. 12. 2025 · NCT06943521Z ClinicalTrials.gov, dáta načítané 5. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.